| Purpose:By observing the TCM syndrome score,duration and frequency of atrial fibrillation,Pittsburgh sleep quality index and safety index before and after treatment,the clinical efficacy and safety of Huatan Quyu Compound on paroxysmal atrial fibrillation with sleep disorder of phlegm turbidity and blood stasis type were discussed.Material and method:From September 2020 to December 2022,60 patients with paroxysmal atrial fibrillation and sleep disorder of phlegm turbidity and blood stasis type were selected from the Department of Geriatrics / Geriatrics,Affiliated Hospital of Liaoning University of Traditional Chinese Medicine.According to the principle of randomization,they were randomly divided into study group and control group,30 cases in each group.The patients in the control group were treated with amiodarone hydrochloride tablets,and the patients in the study group were treated with Huatan Quyu Compound Intelligent Granules.At the same time,patients with chronic basic diseases continued to take conventional western medicine for 12 weeks as a course of treatment.The TCM syndrome scores,weekly frequency of atrial fibrillation,duration of atrial fibrillation,Pittsburgh sleep quality index and safety index were compared between the two groups before and after treatment.SPSS 26.0 was used for statistical analysis of the above data to evaluate the clinical efficacy and safety of Huatan Quyu Compound on paroxysmal atrial fibrillation with sleep disorders of phlegm turbidity and blood stasis syndrome.Results:Among the 60 patients collected,one patient in the study group and one patient in the control group fell off due to incomplete treatment.There was no significant difference in general data between the two groups(p > 0.05).1.Comparison of TCM syndrome score : The TCM syndrome score of the study group decreased from 28.31 ± 2.88 to 11.38 ± 4.62,and the TCM syndrome score of the control group decreased from 28.83 ± 2.16 to 17.48 ± 4.31.The improvement of clinical symptoms in the study group was more significant(P < 0.01).The total effective rate of the study group was 86.21 %,which was higher than that of the control group(62.07 %)(P < 0.01).2.Comparison of the frequency of atrial fibrillation(times / week): The frequency of atrial fibrillation in the study group was reduced from 13.83 ± 5.13 times / week to 5.24 ± 3.42 times / week,and the frequency of atrial fibrillation in the control group was reduced from 14.79 ± 4.84 times / week to 7.72 ± 3.00 times / week.The study group was superior to the control group(P < 0.01).3.Comparison of atrial fibrillation duration(minutes / day): the duration of the study group was reduced from 204.83 ± 170.10 minutes / day to 70.34 ± 46.50 minutes / day,and the duration of the control group was reduced from 196.90 ± 161.89 minutes / day to 102.11 ± 65.45 minutes / day.The treatment effect of the study group was obvious(P < 0.01).4.Pittsburgh sleep quality index : The PSQI score of the study group before treatment was 12.52 ± 1.21 points,which was reduced to 6.66 ± 1.11 points after treatment.The PSQI score of the control group before treatment was 12.34 ± 1.14 points,which was reduced to 8.83 ± 1.26 points after treatment.The sleep quality of the study group was significantly improved(P < 0.01).5.No abnormal laboratory indexes,bleeding events and other adverse reactions occurred in the two groups within three months.Conclusion:In the treatment of patients with paroxysmal atrial fibrillation with sleep disorder of phlegm turbidity and blood stasis type,the compound prescription of resolving phlegm and removing blood stasis can reduce the clinical symptoms,reduce the weekly attack frequency of atrial fibrillation,reduce the attack time of atrial fibrillation,improve the quality of sleep,and have no adverse events.The compound prescription of resolving phlegm and removing blood stasis is superior to the single curative effect of western medicine and has greater clinical value. |
PDF Full Text Request